A study presented at ESTRO 2026 in Stockholm found that prostate cancer radiotherapy delivered in two larger doses over eight days was as safe and effective as a conventional five-fraction schedule, without additional side effects. The trial’s design and outcomes are aimed at reducing treatment burden while maintaining comparable clinical performance. For patients, shorter regimens can improve convenience and reduce exposure to repeated clinic visits; for providers and payers, shorter courses can affect workflow and capacity. In the broader sector context, these results add to growing momentum behind hypofractionation and streamlined scheduling approaches that can widen access to radiotherapy while preserving outcomes.